DoW Autism Clinical Trial Award
About
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e. g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest. Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i. e., Initiating PI) with an Early-Career Investigator (i. e., Partnering PI) wishing to pursue a career in autism clinical trial research. FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applica.
The DoW Autism Clinical Trial Award supports researchers and clinical teams pursuing innovative clinical trials that advance treatment and management options for autism spectrum disorder. This nationwide grant program is designed for investigators ready to implement rapid clinical trials with significant potential impact—from small proof-of-concept studies to large-scale efficacy trials. The program welcomes research evaluating promising new products, pharmacologic agents, devices, clinical guidance, and emerging technologies. A distinctive feature is the Partnering PI Option, which offers enhanced funding to experienced investigators who mentor Early-Career Investigators entering autism clinical trial research. All applicants must establish equitable community collaborations to ensure research translates into real-world impact. If you're leading a research team with a viable autism clinical trial concept and commitment to community engagement, this award provides the funding and support structure to move your work forward. The FY26 cycle particularly encourages applications addressing designated Areas of Interest within autism research.
Funding Facts
● Applications openDeadline
October 22, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by proposal scope and trial phase
Deadline
2026-10-22
Grant Type
federal
Application Cycle
Annual (FY26 cycle with October 22, 2026 deadline)
Best For
Clinical researchers, academic institutions, and research teams conducting autism clinical trials with community engagement
Frequently Asked Questions
Who is eligible for DoW Autism Clinical Trial Award?
Specific eligibility criteria are not provided in the available information. Typically, these awards support Principal Investigators at research institutions, academic medical centers, and organizations capable of conducting clinical trials. The program offers a special Partnering PI Option for Early-Career Investigators paired with experienced mentors. For complete eligibility requirements, visit the official program announcement or sponsoring agency website.
How much funding does DoW Autism Clinical Trial Award provide?
Specific funding amounts are not listed in the available program details. Award amounts typically vary based on the trial design, scope, and phase of research proposed. Contact the sponsoring agency directly or review the official program solicitation for current funding ranges and maximum award limits for FY26.
What types of clinical trials does this award support?
The DoW Autism Clinical Trial Award supports a wide range of trial designs, including small proof-of-concept studies (pilot, first-in-human, phase 0), feasibility trials, and large-scale efficacy trials. Supported research may evaluate new products, pharmacologic agents (drugs or biologics), medical devices, clinical guidance, and emerging approaches or technologies for autism treatment and management.
What is required in my application?
All FY26 applications must include community collaborations with meaningful participation from community members to optimize research impact and translational potential. Applications are strongly encouraged to address one of the designated FY26 Autism Research Program Clinical Trial Award Areas of Interest. Teams applying for the Partnering PI Option must clearly establish the mentorship relationship between an Initiating PI and Early-Career Investigator.
Last updated: July 5, 2026